Interferon β-1a in primary progressive MS: An exploratory, randomized, controlled trial

Neurology

Volumn 60, Issue 1, 2003, Pages 44-51

  Leary, S M ^b   Miller, D H ^b   Stevenson, V L ^b   Brex, P A ^b   Chard, D T ^b   Thompson, A J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; LIVER ENZYME; PLACEBO;

ADULT; ARTICLE; BRAIN VENTRICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; LIVER TOXICITY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0037435526     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.60.1.44     Document Type: Article

References (34)

1. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-1096.
2. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: a distinct syndrome? Mult Scler 1996;2:137-141.
3. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134.
4. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:113-146.
5. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
6. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-765.
7. Leary SM, Stevenson VL, Miller DH, Thompson AJ. Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis. J Neurol 1999;246:562-568.
8. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
9. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
10. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
11. European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-1497.
12. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of recombinant interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001;56:1496-1504.
13. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
14. Comi G, Filippi M, Barkhof F, et al. Effect of early treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
15. Paty DW. MRI data from the North American Study of interferon beta 1b in secondary progressive multiple sclerosis. Rev Neurol 2000;156(suppl 3):S39. Abstract.
16. Cohen JA, Goodman AD, Heidenreich FR, et al. Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive multiple sclerosis. Neurology 2001;56:A148. Abstract.
17. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
19. Filippi M, Gawne-Cain ML, Gasperini C, et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-244.
20. Tofts PS, Barker GJ, Simmons A, et al. Correction of nonuniformity in images of the spine and optic nerve from fixed receive-only surface coils at 1.5T. J Comput Assist Tomogr 1994;18:997-1003.
21. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to measure disease progression. Brain 1996;119:701-708.
22. Fox NC, Freeborough PA. Brain atrophy measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging 1997;7:1069-1075.
23. Clanet M, Kappos L, Radue EW, et al. Results of the European interferon beta-1a (Avonex) dose-comparison study. J Neurol 2001;248(suppl 2):63. Abstract.
24. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988;69:850-854.
25. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis composite as a clinical trial outcome measure. Brain 1999;122:871-882.
26. Ingle GT, Stevenson VL, Miller DH, et al. Two year follow-up study of primary and transitional progressive multiple sclerosis. Mult Scler 2002;8:108-114.
27. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255-260.
28. Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler 2001;7:75-82.
29. Paolillo A, Pozzilli C, Gasperini C, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes,' disease duration and clinical disability. J Neurol Sci 2000;174:85-91.
30. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000;123:2256-2263.
31. Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler (in press).
32. Montalban X, Tintore M, Rio J, et al. Primary progressive multiple sclerosis: description of 121 patients and study design of a controlled trial. Mult Scler 1998;4:344. Abstract.
33. Kita M, Goodkin DE, Bacchetti P, et al. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis. Neurology 2000;54(suppl 3):A22. Abstract.
34. Wolinsky JS, Narayana PA, The PROMiSe trial Study Group. Characteristics at entry into the glatiramer acetate study of primary progressive multiple sclerosis: The PROMiSe Trial. J Neurol 2001;248(suppl 2):134. Abstract.